Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Illumina, Inc.

NASDAQ

Market Cap.

16.96B

Avg. Volume

1.6M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Illumina, Inc.!

Still processing it, give me a bit more time...

Illumina, Inc. News

Illumina, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareMedical - Diagnostics & Research
illumina.com

About Illumina, Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Illumina, Inc. Earnings & Revenue

Illumina, Inc. Financials

Table Compare

Compare ILMN metrics with:

   

Earnings & Growth

ILMN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ILMN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ILMN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ILMN

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Illumina, Inc. Income

Illumina, Inc. Balance Sheet

Illumina, Inc. Cash Flow

Illumina, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquitySell
Return on AssetsNeutral
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Illumina, Inc. Executives

NameRole
Mr. Charles E. Dadswell Esq.Senior Vice President & General Counsel
Dr. Joydeep Goswami M.B.A., Ph.D.Advisor
Mr. Jacob Thaysen Ph.D.Chief Executive Officer & Director
Ms. Carissa L. RollinsChief Information Officer
Mr. Scott EricksenVice President & Chief Accounting Officer
NameRoleGenderDate of BirthPay
Mr. Charles E. Dadswell Esq.Senior Vice President & General CounselMale19591.03M
Dr. Joydeep Goswami M.B.A., Ph.D.Advisor1971843.55K
Mr. Jacob Thaysen Ph.D.Chief Executive Officer & DirectorMale1975796.63K
Ms. Carissa L. RollinsChief Information OfficerFemale1970693.52K
Mr. Scott EricksenVice President & Chief Accounting OfficerMale1973

--

Illumina, Inc. Insider Trades

Date16 May
NameRICHO ANNA
RoleDirector
TransactionAcquired
TypeA-Award
Shares2622
Date16 May
NameRICHO ANNA
RoleDirector
TransactionDisposed
Type
Shares0
Date15 May
NameDORSA CAROLINE
RoleDirector
TransactionDisposed
TypeF-InKind
Shares612
Date16 May
NameDORSA CAROLINE
RoleDirector
TransactionAcquired
TypeA-Award
Shares2622
Date16 May
NameARNOLD FRANCES
RoleDirector
TransactionAcquired
TypeA-Award
Shares2622
DateNameRoleTransactionTypeShares
16 MayRICHO ANNADirectorAcquiredA-Award2622
16 MayRICHO ANNADirectorDisposed0
15 MayDORSA CAROLINEDirectorDisposedF-InKind612
16 MayDORSA CAROLINEDirectorAcquiredA-Award2622
16 MayARNOLD FRANCESDirectorAcquiredA-Award2622

Discover More

Streamlined Academy

Illumina, Inc.

NASDAQ

Market Cap.

16.96B

Avg. Volume

1.6M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Illumina, Inc. News

Illumina, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Illumina, Inc. Earnings & Revenue

Illumina, Inc. Income

Illumina, Inc. Balance Sheet

Illumina, Inc. Cash Flow

Illumina, Inc. Financials Over Time

Illumina, Inc. Executives

NameRole
Mr. Charles E. Dadswell Esq.Senior Vice President & General Counsel
Dr. Joydeep Goswami M.B.A., Ph.D.Advisor
Mr. Jacob Thaysen Ph.D.Chief Executive Officer & Director
Ms. Carissa L. RollinsChief Information Officer
Mr. Scott EricksenVice President & Chief Accounting Officer
NameRoleGenderDate of BirthPay
Mr. Charles E. Dadswell Esq.Senior Vice President & General CounselMale19591.03M
Dr. Joydeep Goswami M.B.A., Ph.D.Advisor1971843.55K
Mr. Jacob Thaysen Ph.D.Chief Executive Officer & DirectorMale1975796.63K
Ms. Carissa L. RollinsChief Information OfficerFemale1970693.52K
Mr. Scott EricksenVice President & Chief Accounting OfficerMale1973

--

Illumina, Inc. Insider Trades

Date16 May
NameRICHO ANNA
RoleDirector
TransactionAcquired
TypeA-Award
Shares2622
Date16 May
NameRICHO ANNA
RoleDirector
TransactionDisposed
Type
Shares0
Date15 May
NameDORSA CAROLINE
RoleDirector
TransactionDisposed
TypeF-InKind
Shares612
Date16 May
NameDORSA CAROLINE
RoleDirector
TransactionAcquired
TypeA-Award
Shares2622
Date16 May
NameARNOLD FRANCES
RoleDirector
TransactionAcquired
TypeA-Award
Shares2622
DateNameRoleTransactionTypeShares
16 MayRICHO ANNADirectorAcquiredA-Award2622
16 MayRICHO ANNADirectorDisposed0
15 MayDORSA CAROLINEDirectorDisposedF-InKind612
16 MayDORSA CAROLINEDirectorAcquiredA-Award2622
16 MayARNOLD FRANCESDirectorAcquiredA-Award2622

Streamlined Academy

Website screenshot
HealthcareMedical - Diagnostics & Research
illumina.com

About Illumina, Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Illumina, Inc.!

Still processing it, give me a bit more time...

Illumina, Inc. Financials

Table Compare

Compare ILMN metrics with:

   

Earnings & Growth

ILMN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ILMN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ILMN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ILMN

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Illumina, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquitySell
Return on AssetsNeutral
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More